Manejo del edema macular diabético refractario con Ozurdex®. Respuesta clínica [PDF]
, 2017 El edema macular diabético (EMD) constituye una entidad de gran repercusión socio-sanitaria. Tiene una prevalencia elevada y en aumento dentro de los pacientes con retinopatía diabética (RD), suponiendo una importante sobrecarga asistencial en los ...
Fernández Gutiérrez, Javier
core
The Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery. [PDF]
, 2022 The Port Delivery System with ranibizumab (PDS) is an innovative intraocular drug delivery system designed for the continuous delivery of ranibizumab into the vitreous for 6 months and beyond.
Barteselli, Giulio +9 more
core +1 more source
Intravitreal ILUVIEN® Implant for Diabetic Macular Oedema – Early Case Experiences
European Ophthalmic Review, 2013 Diabetic macular oedema (DMO) is an important cause of vision loss and challenges remain in the treatment of this progressive disease. Corticosteroids provide a comprehensive treatment approach, lowering the concentration of inflammatory cytokines and growth factors such as vascular endothelial growth factor (VEGF). However, intravitreal injections are
Anke Messerschmidt-Roth +1 more
openaire +1 more source
Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom [PDF]
Eye, 2017 AimsTo compare safety outcomes and visual function data acquired in the real-world setting with FAME study results in eyes treated with 0.2 μg/day fluocinolone acetonide (FAc).MethodsFourteen UK clinical sites contributed to pseudoanonymised data collected using the same electronic medical record system. Data pertaining to eyes treated with FAc implant
Bailey, C +4 more
openaire +2 more sources
Ophtalmologie. Rétinopathie diabétique: nouvelles possibilités thérapeutiques [Diabetic retinopathy: new therapeutic possibilities]. [PDF]
, 2015 La rétinopathie diabétique touche un nombre croissant de personnes, soit quatre millions en Europe, ce chiffre va probablement doubler d'ici 2030. Si l'on considère que 25-30% de ces patients sont atteints de rétinopathie diabétique, un dépistage et un ...
Behar-Cohen, F., Guex-Crosier, Y.
core
Letter to the editor: dexamethasone intravitreal implant in the treatment of diabetic macular edema
Clinical Ophthalmology, 2015 John Hall Alimera Sciences Ltd., Aldershot, Hampshire, UK I read “Dexamethasone intravitreal implant in the treatment of diabetic macular edema” published July 2015 by Dugel et al.1This article is very interesting in terms of providing an
Hall J
doaj
Evaluation of fluocinolone acetonide 0.19 mg intravitreal implant in the management of birdshot retinochoroiditis [PDF]
, 2020 Purpose: To report treatment outcomes and efficacy of the fluocinolone acetonide 0.19 mg intravitreal implant (Iluvien) in controlling retinal and choroidal inflammation in 11 patients with birdshot retinochoroiditis.
Ajamil-Rodanes, S +5 more
core
Intravitreal fluocinolone acetonide 0.19 mg Iluvien implant for radiation maculopathy
Canadian Journal of OphthalmologyTo evaluate the efficacy of a long-acting fluocinolone acetonide 0.19 mg Iluvien intravitreal (FAc) implant for the treatment of radiation maculopathy (RM).Retrospective case series.Seven patients treated for uveal melanoma with palladium-103 plaque brachytherapy who developed RM.Patients initially received intravitreal anti-vascular endothelial growth
Paul T. Finger +2 more
openaire +2 more sources
Therapeutic Advances in Ophthalmology, 2019 Introduction: Macular edema after central retinal vein occlusion is a common cause of vision loss. Upregulation of vascular endothelial growth factor and higher levels of inflammatory mediators have been involved in the pathogeny of the macular edema in ...
João Coelho +2 more
doaj +1 more source